Conference Science Medal 1997 lecture at British Pharmaceutical Conference, Scarborough, United Kingdom, September 15-18, 1997: Recent advances in vaccine adjuvants for systemic and mucosal administration

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 1, 1998, Pages 1-10

  O'Hagan, Derek T ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; ESCHERICHIA COLI ENTEROTOXIN; HEPATITIS B VACCINE; HERPES VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LIVE VACCINE; LTK 63; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PERTUSSIS VACCINE; POLYGLACTIN; POLYSACCHARIDE VACCINE; TOXOID; UNCLASSIFIED DRUG; VACCINE; BACTERIAL VACCINE; DNA; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS VACCINE;

AMINO ACID SUBSTITUTION; BIODEGRADATION; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; DRUG DETOXIFICATION; DRUG SAFETY; GENETICS; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; META ANALYSIS; MICROEMULSION; MUCOSAL IMMUNITY; PATIENT COMPLIANCE; RECOMBINANT DNA TECHNOLOGY; SITE DIRECTED MUTAGENESIS; THERMOSTABILITY; VACCINATION; VACCINE PRODUCTION; BACTERIAL INFECTION; IMMUNOLOGY; REVIEW; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; BACTERIAL INFECTIONS; BACTERIAL VACCINES; DNA; HUMANS; POLYSORBATES; SQUALENE; VACCINES; VIRAL VACCINES; VIRUS DISEASES;

EID: 85044700671     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb03298.x     Document Type: Conference Paper

References (55)

1. Alving, C. R. (1992) Immunologic aspects of liposomes. Presentation and processing of liposomal protein and phospholipid antigens. Biochim. Biophys. Acta 1113: 307-322
2. Bengtsson, K. L., Sjölander, A. (1996) Adjuvant activity of iscoms: effect of ratio and co-incorporation of antigen and adjuvant. Vaccine 14: 753-760
3. Cahill, E. S., O'Hagan, D. T., Ilum, L., Barnard, A., Mills, K. H. G., Redhead, K. (1995) Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin. Vaccine 13: 455-462
4. Challacombe, S. J., Rahman, D., Jeffery, H., Davis, S. S., O'Hagan, D. T. (1992) Enhanced secretory IgA and systemic IgG after oral immunization with biodegradable microparticles. Immunology 76: 164-168
5. Cleland, J. L., Powell, M. F., Lim, A., Barron, L., Berman, P. W., Eastman, D. J., Nunberg, J. H., Wrin, T., Vennari, J. C. (1994) Development of a single-shot sub-unit vaccine for HIV-1. AIDS Res. Hum. Retro. 10: S21-S26
6. Couch, R. B. (1993) Advances in influenza virus vaccine research. Ann. NY Acad. Sci. 685: 803-812
7. Di Tommaso, A., Saleti, G., Pizza, M., Rappuoli, R., Dougan, G., Abrignani, S., Douce, G., De Magistris, T. (1996) Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heal labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64: 974-979
8. Donnelly, J. J., Ulmer, J. B., Liu, M. A. (1997) DNA vaccines. Life Sci. 60: 163-172
9. Douce, G., Turcotte, C., Cropley, I., Roberts, M., Pizza, M., Domenghini, M., Rappuoli, R., Dougan, G. (1995) Mutants of Escherichia coli heat-labile enterotoxin lacking ADP-ribosyl transferase activity act as non-toxic mucosal adjuvants. Proc. Natl Acad. Sci. USA 92: 1644-1648
10. Douce, G., Fontana, M., Pizza, M., Rappuoli, R., Dougan, G. (1997) Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of Cholera toxin. Infect. Immun. 65: 2821-2828
11. Eldridge, J. H., Hammond, C. J., Meulbroek, J. A., Staas, J. K., Gilley, R. M., Tice, T. R. (1990) Controlled vaccine release in the gut associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Contr. Rel. 11:205-214
12. Eldridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., Gilley, R. M. (1991) Biodegradable and biocompatible poly (DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59: 2978-2986
13. Granoff, D. M., McHugh, Y. E., Raff, H. V., Mokatrin, A. S., Van Nest, G. (1997) MF59 adjuvant enhances antibody responses of infant baboons immunized with haemophilus influenzae Type b and Neisseria meningitidis Group C oligosaccharide-CRM197 conjugate vaccine. Infect. Immun. 65: 1710-1715
14. Gregoriadis, G. (1990) Immunological adjuvants: a role for liposomes. Immunol. Today 11: 89-97
15. Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben-Eftaim, S., Gupta, C. K. (1993) Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 10: 96-97
16. Gupta, R. K., Rost, B. E., Relyveld, E., Siber, G. R. (1995) Adjuvant properties of aluminium and calcium compounds. In: Powell, M. F., Newman, M. J. (eds) Vaccine Design, The Sub-unit and Adjuvant Approach. Plenum Press, New York, pp 229-248
17. Johnson, O. L., Cleland, J. L., Lee, H. J., Charnis, M., Duenas, E., Jaworowicz, W., Shepard, D., Shahzamani, A., Jones, A. J. S., Putney, S. D. (1996) A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med. 2: 795-799
18. Jones, D. H., McBride, B. W., Thornton, C., O'Hagan, D. T., Robinson, A., Farrar, G. H. (1996) Oral immunization with microencapsulated pertussis fimbriae induces protective immunity in mice. Infect. Immun. 64: 489-494
19. Kahn, J. O., Sinangil, F., Baenziger, J., Murcar, N., Wynne, D., Coleman, R. L. (1994) Clinical and immunologic responses to human immunodeficiency virus (HIV) Type I SF2 gp120 sub-unit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non HIV-infected human volunteers. J. Infect. Dis. 170: 1288-1291
20. Kato, T., Owen, R. L. (1994) Structure and function of intestinal mucosal epithelium. In: Ogra, P. L., Lamm, M. E., McGhee, J. R., Mestecky, J., Strober, W., Bienenstock, J. (eds) Handbook of Mucosal Immunology. Academic Press, San Diego, pp 11-26
21. Kiyono, H., Ogra, P. L., McGhee, J. R. (1996) Mucosal Vaccines. Academic Press, San Diego
22. Langenberg, A. G. M., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. (1995) A recombinant glycoprotein vaccine for herpes simplex type 2: safety and immunogenicity. Ann. Intern. Med. 122: 889-898
23. Levine, M. M., Woodrow, G. C., Kaper, J. B., Cobon, G. S. (1997) New Generation Vaccines. 2nd edn, Marcel Dekker, New York
24. Livingston, P. O., Adluri, S., Helling, F., Yao, T. J., Kensil, C. R., Newman, M. J., Marciani, D. (1994) Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma. Vaccine 12: 1275-1280
25. Maloy, K. J., Donachie, A. M., O'Hagan, D. T., Mowat, A. M. (1994) Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81: 661-667
26. Manickan, E., Karem, K. L., Rouse, B. T. (1997) DNA vaccines - A modern gimmick or a boon to vaccinology. Crit. Rev. Immunol. 17: 139-154
27. Marx, P. A., Compans, R. W., Gettie, A., Staas, J. K., Gilley, R. M., Mulligan, M. J., Yamschchikov, G. V., Chen, D., Eldridge, J. H. (1993) Protection against vaginal SIV transmission with microencapsulated vaccine. Science 260: 1323-1327
28. Matiowitz, E., Jacob, J. S., Jong, Y. S., Carino, G. P., Chickering, D. E., Chaturvedi, P., Santos, C. A., Vijayaraghavan, K., Montgomery, S., Bassett, M., Morrell, C. (1997) Biologically credible microspheres as potential oral drug delivery systems. Nature 386: 410-414
29. + Th1 cells. Vaccine 13: 1741-1749
30. O'Hagan, D. T. (1994) Microparticles as oral vaccines. In: O'Hagan, D. T. (ed.) Novel Delivery Systems for Oral Vaccines. CRC Press, Boca Raton, pp 175-205
31. O'Hagan, D. T. (1996) The intestinal uptake of particles and the implications for drug and antigen delivery. J. Anat. 189: 477-482
32. O'Hagan, D. T. (1997) Prospects for the development of new and improved vaccines through the use of microencapsulation technology. In: Levine, M. M., Woodrow, G. C., Kaper, J. B., Cobon, G. S. (eds) New Generation Vaccines. 2nd edn, Marcel Dekker, New York, pp 215-228
33. O'Hagan, D. T., Rahman, D., McGee, J. P., Jeffery, H., Davies, M. C., Williams, P., Davis, S. S., Challacombe, S. J. (1991a) Biodegradable microparticles as controlled-release antigen delivery systems. Immunology 73: 239-242
34. O'Hagan, D. T., Jeffery, H., Roberts, M. J. J., McGee, J. P., Davis, S. S. (1991b) Controlled-release microparticles for vaccine development. Vaccine 9: 768-771
35. O'Hagan, D. T., Jeffery, H., Davis, S. S. (1993) Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 11: 965-969
36. O'Hagan, D. T., McGee, J. P., Boyle, R., Gumaer, D., Li, J., Potts, B., Wang, C. Y., Koff, W. C. (1995) The preparation, characterization and pre-clinical evaluation of an orally administered HIV-1 vaccine, consisting of a branched synthetic peptide immunogen entrapped in controlled-release microparticles. J. Contr. Rel. 36: 75-84
37. Ott, G., Van Nest, G., Burke, R. L. (1992) The use of muramyl peptides as vaccine adjuvants. In: Koff, W., Six, H. R. (eds) Vaccine Research and Development. Marcel Dekker, pp 89-114
38. Ott, G., Barchfeld, G., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., Van Nest, G. (1995) MF59: design and evaluation of a safe and potent adjuvant for human use. In: Powell, M., Newman, M. (eds) Vaccine Design: The Sub-unit and Adjuvant Approach. Plenum Press, New York, pp 277-294
39. Pizza, M., Covacci, A., Bartoloni, A., Perugini, M., Nencioni, L., De Magistris, T., Villa, L., Nucci, D., Manetti, R., Bugnoli, M., Giovannoni, F., Olivieri, R., Barbieri, J., Sato, H., Rappuoli, R. (1989) Mutants of pertussis toxin suitable for vaccine development. Science 246: 497-500
40. Pizza, M., Fontana, M. R., Giuliani, M. M., Domenighini, M., Magagnoli, C., Giannelli, V., Nucci, D., Hol, W., Manetti, R., Rappuoli, R. (1994) A genetically detoxified derivative of heat-labile E. coli enterotoxin induces neutralizing antibodies against the A sub-unit. J. Exp. Med. 180: 2147-2153
41. Plotkin, S., Mortimer, E. A. (1988) Vaccines. W. B. Saunders and Company, New York
42. Ramon, G. (1924) Sur la toxine et sur l'anatoxine diphtheriques. Ann. Inst. Pasteur 38: 1-10
43. Rappuoli, R. (1997) Rational design of vaccines. Nat. Med. 4: 374-376
44. Rothbrock, G., Smithee, L., Rados, M., Baughman, W. (1995) Progress toward the elimination of Haemophilus influenzae type b disease among infants and children - United States, 1993-1994. J. Am. Med. Assoc. 274: 1334-1338
45. Shahin, R., Leef, M., Eldridge, J. H., Hudson, M., Gilley, R. (1995) Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect. Immun. 63: 1195-1200
46. Singh, M., Li, X.-M., Wang, H., McGee, J. P., Zamb, T., Koff, W., Wang, C.-Y., O'Hagan, D. T. (1997) Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect. Immun. 65: 1716-1721
47. Soltysik, S., Wu, J.-Y., Recchia, J., Wheeler, D. A., Newman, M. J., Coughlin, R. T., Kensil, C. R. (1995) Structure/function studies of QS21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13: 1403-1410
48. Traquina, P., Morandi, M., Contorni, M., Van Nest, G. (1996) MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 174: 1168-1175
49. Tseng, J., Komisar, J. L., Trout, R. N., Hunt, R. E., Chen, J., Johnson, A. J., Pitt, J., Ruble, D. L. (1995) Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. Infect. Immun. 63: 2880-2885
50. Ulrich, J. T., Ulrich, K. R. (1995) Monophosphoryl lipid A as an adjuvant: past experiences and new directions. In: Powell, M., Newman, M. (eds), Vaccine Design: The Sub-unit and Adjuvant Approach. Plenum Press, New York, pp 495-524
51. Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G., Hall, B. D. (1982) Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298: 347-350
52. Weiner, H. L. (1997) Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today 19: 335-343
53. Williams, N. (1996) An immune boost to the war on cancer. Science 272: 28-30
54. Wise, D. L., Fellman, T. D., Sanderson, J. E., Wentworth, R. L. (1979) Lactide/glycolide polymers used as surgical suture material, raw material for osteosynthesis and in sustained release of drugs. In: Gregoriadis, G. (ed.), Drug Carriers in Medicine. Academic Press, New York, pp 237-270
55. Zhou, F., Kraehenbuhl, J.-P., Neutra, M. R. (1995) Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes. Vaccine 13: 637-644